| Abstract P096 – Table 1. Demographic, clinical, therapeutic and virological characteristics of the overall population and in individuals eligible and ineligible for LA CAB+RPV. Potential differences between eligible and ineligible individuals to CAB+RPV were evaluated by T‐test or Mann‐Whitney exact test for quantitative variables and Chi‐squared/Fisher's tests for qualitative variables, as appropriate. | ||||
|---|---|---|---|---|
| Variables | Overall population (n = 514) | Non‐eligible for CAB+RPV (n = 285) | Eligible for CAB+RPV (n = 229) | p‐value |
| Gender male, n (%) | 377 (73.3) | 198 (69.5) | 179 (78.2) | 0.034 |
| Age (years), median (IQR) | 51 (43 to 58) | 54 (46 to 58) | 48 (38 to 55) | <0.001 |
| Ethnicity, n (%) | ||||
| Caucasian | 314 (60.0) | 169 (59.3) | 145 (63.3) | 0.353 |
| Black | 36 (7.0) | 25 (8.7) | 11 (4.8) | 0.114 |
| Other/unknown | 164 (33.0) | 91 (32.0) | 73 (31.9) | 0.597 |
| HIV‐1 subtype, n (%) | ||||
| B | 382 (74.3) | 225 (78.9) | 157(68.6) | 0.007 |
| Aa | 19 (3.7) | 6 (2.1) | 13 (5.7) | 0.058 |
| CRF02_AG | 43 (8.4) | 24 (8.4) | 19 (8.3) | 1.000 |
| CRFs_BC | 18 (3.5) | 2 (0.7) | 16 (7.0) | <0.001 |
| CRFs_BF | 11 (2.1) | 6 (2.1) | 5 (2.2) | 1.000 |
| Others | 41 (8.0) | 22 (7.7) | 19 (8.3) | 0.939 |
| HIV‐1 risk factor, n (%) | ||||
| Heterosexual | 212 (41.2) | 118 (41.4) | 94 (41.1) | 0.935 |
| MSM | 121 (23.5) | 57 (20.0) | 64 (27.9) | 0.035 |
| Drugs injection | 96 (18.7) | 75 (26.3) | 21 (9.2) | <0.001 |
| Other/unknown | 85 (16.5) | 35 (12.3) | 50 (21.8) | 0.005 |
| VL zenith (log10 copies/mL), median (IQR) | 4.9 (4.0 to 5.5) | 5.1 (4.4 to 5.7) | 4.5 (3.1 to 5.2) | <0.001 |
| CD4 count nadir (cells/mm3), median (IQR) | 210 (80 to 370) | 170 (50 to 320) | 260 (120 to 450) | <0.001 |
| Year of HIV‐1 diagnosis, median (IQR) | 2008 (1995 to 2014) | 2002 (1991 to 2011) | 2012 (2006 to 2016) | <0.001 |
| HCV co‐infection, n (%) | 65 (12.6) | 53 (18.6) | 12 (5.2) | <0.001 |
| HBV co‐infection, n (%) | 41 (8.0) | 41 (14.4) | 0 (0.0) | − |
| First therapy (year), median (IQR) | 2011 (2003 to 2016) | 2007 (1997 to 2014) | 2015 (2010 to 2017) | <0.001 |
| Years from first therapy, median (IQR) | 9 (4 to 17) | 13 (6 to 23) | 6 (3 to 10) | <0.001 |
| Previous drug classes experienced, n (%) | ||||
| NRTI | 498 (98.6) | 276 (97.9) | 222 (99.6) | 0.14 |
| NNRTI | 315 (62.4) | 194 (68.8) | 121 (54.3) | <0.001 |
| PI | 349 (69.1) | 227 (80.5) | 122 (54.7) | <0.001 |
| INSTI | 388 (76.8) | 244 (86.5) | 144 (64.6) | <0.001 |
| MVC | 35 (6.9) | 28 (9.9) | 7 (3.1) | 0.005 |
| T20 | 17 (3.4) | 17 (6.0) | 0 (0.0) | <0.001 |
| No. of previous therapies, median (IQR) | 4 (2 to 7) | 6 (3 to 11) | 3 (2 to 4) | < 0.001 |
| Therapy at last viraemia, n (%) (n = 497) | ||||
| 2 NRTI + 1 INSTI | 179 (36.0) | 101 (36.6) | 78 (35.6) | 0.869 |
| 2 NRTI + 1 NNRTI | 106 (21.3) | 32 (11.5) | 74 (33.8) | <0.001 |
| 2 NRTI + 1 PI | 62 (12.5) | 38 (13.7) | 24 (11.0) | 0.441 |
| 1 NRTI + 1 INSTI | 39 (7.8) | 16 (5.8) | 23 (10.5) | 0.074 |
| Other | 111 (22.3) | 91 (32.7) | 20 (9.1) | <0.001 |
| Previous VFs, n (%) | ||||
| NNRTI | 136 (26.4) | 136 (47.7) | − | − |
| RPV | 17 (3.3) | 17 (6.0) | − | − |
| INSTI | 119 (23.2) | 119 (41.8) | − | − |
| Time from last VF (months), median (IQR) | 63 (34.7 to 105.2) | 62.1 (34 to 102) | 64.4 (36.2 to 107.6) | 0.583 |
| At least one major RAM for INSTI, n (%) | 33 (6.4) | 33 (11.6) | 0 (0) | − |
| At least one RAM for NNRTI, n (%) | 168 (32.7) | 168 (58.9) | 0 (0) | − |
| At least one RAM for RPV, n (%) | 104 (20.2) | 104 (36.5) | 0 (0) | − |
| CAB + RPV cumulative GSS, median (IQR) | 2 (1.5 to 2) | 1.5 (1 to 2) | 2 (2 to 2) | <0.001 |
CAB, cabotegravir; GSS, genotypic susceptibility score (according to Stanford algorithm; HIVdb version 9.0, https://hivdb.stanford.edu/); INSTI, integrase strand transfer inhibitor; IQR, interquartile range; LA, long‐acting; MVC, maraviroc; PI, protease inhibitor; RAM, resistance associated mutation; RPV, rilpivirine; VF, virological failure; VL, viral load.
aSubtype A1/A6: n = 17; subtype A7: n = 2.